Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.


Trade Name(s)

  • Dicetel Canadian Trade name

Ther. Class.

anti irritable bowel syndrome agents

Pharm. Class.

calcium channel blockers


  • Management of symptoms of irritable bowel syndrome, (IBS) including abdominal pain, bowel disturbances and discomfort.
  • Treatment of symptoms related to biliary tract disorders.


  • Acts as a calcium channel blocker with specific selectivity for intestinal smooth muscle.
  • Relaxes gastrointestinal (mainly colon) and biliary tracts, inhibits colonic motor response to food/pharmacologic stimulation.

Therapeutic Effect(s):

Decreased symptoms of IBS.


Absorption: Poorly absorbed (1–10%).

Distribution: Distributes selectively to digestive tract.

Protein Binding: 97%.

Metabolism and Excretion: Minimal enterohepatic cycling, eliminated almost entirely in feces. Some metabolism.

Half-life: 1.5 hr.

TIME/ACTION PROFILE (blood levels)

POunknown1 hr unknown


Contraindicated in:

  • Known hypersensitivity;
  • Galactose intolerance/Lapp lactase deficiency/glucose-galactose malabsorption (tablets contain lactose);
  • Lactation: Avoid use if breastfeeding;
  • Pedi:  Safety and effectiveness not established, use is not recommended.

Use Cautiously in:

  • Pre-existing esophageal lesions/hiatal hernia (glass of water and snack should be taken with each dose);
  • OB:  Should be used only if essential to welfare of patient.

Adverse Reactions/Side Effects

All less than 1%

CNS: drowsiness, headache, vertigo

GI: constipation, diarrhea, distention, dry mouth, epigastric pain/fullness, esophageal irritation, nausea

Derm: rash

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Concurrent use of  anticholinergics  may ↑ spasmolytic effects.


PO (Adults): 50 mg 3 times daily; may be ↑ as needed/tolerated up to 100 mg 3 times daily.


Tablets (contain lactose): 50 mg, 100 mg


  • Assess for symptoms of IBS (abdominal pain or discomfort, bloating, constipation).
  • Assess for lactose intolerance; product contains lactose.


  • PO Administer tablet with a glass of water and food. Swallow tablet whole, do not crush, chew, or suck. If >3 tablets/day prescribed, take additional tablets with glass of water and a snack. May be irritating to esophagus. Do not take the tablet while lying down or just before bedtime.

Patient/Family Teaching

  • Instruct patient to take pinaverium as directed. Take missed doses as soon as remembered unless almost time for next dose; do not double doses.
  • Caution patient to inform health care professional if the following side effects persist or worsen: stomach pain or fullness, nausea, constipation or diarrhea, heartburn, headache, dry mouth, dizziness, skin rash.
  • Instruct patient to avoid alcohol intake while taking this medication.
  • Rep:  Advise females of reproductive potential to inform health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

A decrease in symptoms of irritable bowel syndrome. The length of treatment depends on the condition being treated.